Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Palisade Bio, Inc. on October 17, 2025. The filing details the voting outcomes for three proposals presented to shareholders as of the record date of September 12, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure actions rather than financial performance.
Material Changes and Voting Results
As of the record date, 9,119,152 shares were outstanding. A total of 3,585,700 shares (approximately 39.32%) were present, constituting a quorum. The material changes approved include:
- Election of Directors: Stockholders elected J.D. Finley, Donald Williams, and Emil Chuang to serve until the 2026 annual meeting.
- Auditor Ratification: Stockholders ratified the selection of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Reverse Stock Split Authorization: Stockholders approved an amendment to the Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split at a ratio between 1-for-5 and 1-for-50. The Board may implement this split at its discretion on or before December 31, 2025, without further shareholder approval.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risks beyond the authorization of the reverse stock split. The approval of the reverse split indicates a strategic move to adjust the company's share structure, potentially to meet listing requirements or improve marketability, though the exact timing and ratio remain at the Board's discretion.
Investor Verification Checklist
- Verify the exact reverse stock split ratio and implementation date once announced by the Board of Directors.
- Confirm the impact of the reverse split on the number of shares held and the adjusted share price.
- Review the upcoming 2025 Annual Report (10-K) for financial performance data not included in this 8-K.
- Monitor the company's compliance with Nasdaq Capital Market listing standards following the potential split.